Impact of rosiglitazone on the expression of β3-AR in the stable cell lines expressed β3-AR gene

Clinical Chemistry and Laboratory Medicine

Volumn 45, Issue 11, 2007, Pages 1511-1516

  Zhao, Xin ^a   Hu, Min Yu ^a   Huang, Qiong ^a   Tang, Zhong Yang ^a   Dai, Xing Ping ^a   Yin, Ji Ye ^a   Zhang, Feng ^a   Zhou, Hong Hao ^a   Liu, Zhao Qian ^a  

^a Central South University   (China)

Author keywords

3 adrenergic receptor; Peroxisome proliferator activated receptor 2; Rosiglitazone; Stable cell lines; Transfection

Indexed keywords

BETA 3 ADRENERGIC RECEPTOR; COMPLEMENTARY DNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; ROSIGLITAZONE;

ADULT; ARTICLE; BETA 3 ADRENERGIC RECEPTOR GENE; CASE REPORT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA SEQUENCE; DRUG INHIBITION; ELECTROPORATION; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA TRANSLATION; WESTERN BLOTTING;

BASE SEQUENCE; BLOTTING, WESTERN; CELL LINE, TUMOR; DNA PRIMERS; HUMANS; HYPOGLYCEMIC AGENTS; PLASMIDS; PPAR GAMMA; RECEPTORS, ADRENERGIC, BETA-3; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THIAZOLIDINEDIONES;

EUKARYOTA;

EID: 35648996044     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2007.315     Document Type: Article

References (24)

1. Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990;347:645-50.
2. Neve BP, Fruchart JC, Staels B. Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis. Biochem Pharmacol 2000;60:1245-50.
3. Okura T, Nakamura M, Takata Y, Watanabe S, Kitami Y, Hiwada KT. Rosiglitazone induces apoptosis via the p53 and Gadd45 pathway in vascular smooth muscle cells. Eur J Pharmacol 2000;407:227-35.
4. Tsubouchi Y, Sano H, Kawahito Y, Mukai S, Yamada R, Kohno M, et al. Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-gamma agonists through induction of apoptosis. Biochem Biophys Res Commun 2000;270:400-5.
5. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999;20:649-88.
6. Saladin R, Fajas L, Dana S, Halvorsen YD, Auwerx J, Briggs M. Differential regulation of peroxisome proliferator activated receptor gamma1 (PPARgamma1) and PPARgamma2 messenger RNA expression in the early stages of adipogenesis. Cell Growth Differ 1999;10:43-8.
7. Berger J, Moller DE. The mechanisms of action of PPARs. Annu Rev Med 1999;53:409-35.
8. Strosberg AD. Structure and function of the beta 3-adrenergic receptor. Annu Rev Pharmacol Toxicol 1997;37:421-50.
9. Candelore MR, Deng L, Tota LM, Kelly LJ, Cascieri MA, Strader CD. Pharmacological characterization of a recently described human beta 3-adrenergic receptor mutant. Endocrinology 1996;137:2638-41.
10. Reihsaus E, Innis M, MacIntyre N, Liggett SB. Mutations in the gene encoding for the beta 2-adrenergic receptor in normal and asthmatic subjects. Am J Respir Cell Mol Biol 1993;8:334-9.
11. Walston J, Silver KM, Bogardus C, Knowler WC, Celi FS, Austin S, et al. Time of onset of non-insulin-dependent diabetes mellitus and genetic variation in the beta 3-adrenergic-receptor gene. N Engl J Med 1995;333:343-7.
12. Liu ZQ, Mo W, Yu QJ, Tang Q, Tan YM, Zhou HH. The relationship between the genetic polymorphism of the β3-adrenoceptor and obesity and hypertension. Chin Modern Med 2006;16:1811-4.
13. Mo W, Zhang GG, Yang TL, Dai XP, Li HH, Zeng H, et al. The genetic polymorphisms of β3-AR Trp64Arg and β2-AR Gln27Glu are associated with obesity in Chinese male hypertensive patients. Clin Chem Lab Med 2007;45:493-8.
14. Smith SA, Levy AL, Sennitt MV, Simson DL, Cawthorne MA. Effects of BRL 26830, a novel beta-adrenoceptor agonist, on glucose tolerance, insulin sensitivity and glucose turnover in Zucker (fa/fa) rats. Biochem Pharmacol 1985;34:2425-9.
15. Hussein Z, Wentworth JM, Nankervis AJ, Proietto J, Colman PG. Effectiveness and side effects of thiazolidinediones for type 2 diabetes: real-life experience from a tertiary hospital. Med J Aust 2004;181:536-9.
16. Bakopanos E, Silva JE. Thiazolidinediones inhibit the expression of beta-3 adrenergic receptors at a transcriptional level. Diabetes 2000;49:8-15.
17. Dong Z, Zhang JT. EIF3 p170, a mediator of mimosine effect on protein synthesis and cell cycle progression. Mol Biol Cell 2003;14:3942-51.
18. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54.
19. Chen F, Law SW, O'Malley BW. Identification of two mPPAR related receptors and evidence for the existence of five subfamily members. Biochem Biophys Res Commun 1993;196:671-7.
20. Deeb SS, Fajas L, Nemoto M, Pihlajamaki J, Mykkanen L, Kuusisto J, et al. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998;20:284-7.
21. Mori H, Ikegami H, Kawaguchi Y, Seino S, Yokoi N, Takeda J, et al. The Pro12Ala substitution in PPAR-gamma is associated with resistance to development of diabetes in the general population: possible involvement in impairment of insulin secretion in individuals with type 2 diabetes. Diabetes 2001;50:891-4.
22. Nakamura T, Funahashi T, Yamashita S, Nishida M, Nishida Y, Takahashi M, et al. Thiazolidinedione derivative improves fat distribution and multiple risk factors in subjects with visceral fat accumulation - double-blind placebo-controlled trial. Diabetes Res Clin Pract 2001;54:181-90.
23. Akazawa S, Sun F, Ito M, Kawasaki E, Eguchi K. Efficacy of rosiglitazone on body fat distribution in type 2 diabetes. Diabetes Care 2000;23:1067-71.
24. Shimizu H, Tsuchiya T, Sato N, Shimomura Y, Kobayashi I, Mori M. Rosiglitazone reduces plasma leptin concentration but increases hunger in NIDDM patients. Diabetes Care 1998;21:1470-4.